Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Report 2026

The metabolic dysfunction-associated steatohepatitis (mash) treatment market size has grown exponentially in recent years. It will grow from $3.18 billion in 2025 to $3.88 billion in 2026 at a compound annual growth rate (CAGR) of 22.2%. The growth in the historic period can be attributed to rising prevalence of obesity, increasing incidence of type 2 diabetes, growing awareness of liver health disorders, expansion of diagnostic testing capabilities, early adoption of lifestyle modification programs.

The metabolic dysfunction-associated steatohepatitis (mash) treatment market size is expected to see exponential growth in the next few years. It will grow to $8.6 billion in 2030 at a compound annual growth rate (CAGR) of 22%. The growth in the forecast period can be attributed to increasing adoption of glp-1 agonists, growth in antifibrotic drug development, rising penetration of digital liver monitoring tools, expansion of bariatric surgery usage, increasing focus on personalized metabolic therapies. Major trends in the forecast period include expansion of precision liver disease therapeutics, AI-enabled early detection and risk stratification, cloud-based liver health data management, iot-integrated lifestyle and medication monitoring, growth in sustainable and preventive metabolic health programs.

The rising prevalence of obesity is expected to drive growth in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market in the coming years. Obesity is a medical condition marked by excessive body fat accumulation that can adversely affect overall health, generally assessed by a body mass index (BMI) of 30 or above. The global incidence of obesity is increasing, fueled by sedentary lifestyles, poor dietary habits, and metabolic risk factors. Treatment of metabolic dysfunction-associated steatohepatitis (MASH) in individuals with obesity focuses on managing insulin resistance, reducing liver fat, and enhancing metabolic health through lifestyle interventions and targeted therapies. For example, in March 2023, the World Heart Foundation, a Switzerland-based global cardiovascular non-governmental organization, reported that approximately 2.3 billion adults and children worldwide are currently obese or overweight, and this figure is projected to rise to 2.7 billion by 2025 due to ongoing obesity trends. Consequently, the growing prevalence of obesity is driving demand for metabolic dysfunction-associated steatohepatitis (MASH) treatments.

Key players in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market are concentrating on developing innovative therapies such as liver fibrosis treatment solutions to provide options for patients with MASH and moderate to severe liver fibrosis. These solutions aim to address the underlying causes of liver damage through lifestyle modifications, antiviral drugs, and emerging antifibrotic therapies, with the goal of halting or reversing fibrosis progression and improving liver function. For instance, in March 2024, Madrigal Pharmaceuticals, Inc., a US-based biopharmaceutical company, announced FDA approval of Rezdiffra (resmetirom), the first treatment specifically for metabolic dysfunction-associated steatohepatitis (MASH) with moderate to severe liver fibrosis. Rezdiffra is a daily oral tablet that demonstrated efficacy in resolving MASH without worsening fibrosis and improving liver fibrosis in phase 3 clinical trials. This advancement offers a non-invasive treatment alternative, eliminating the need for liver biopsies and significantly enhancing patient access and outcomes in managing fatty liver disease.

In January 2024, Suzhou Ribo Life Science Co., Ltd., a China-based clinical-stage company, and Ribocure Pharmaceuticals AB (Ribo), a Sweden-based clinical-stage biotechnology firm, announced a $2 billion collaboration with Boehringer Ingelheim. The partnership aims to develop innovative therapies for nonalcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatohepatitis (MASH) by combining Ribo’s RNAi therapeutic platform with Boehringer Ingelheim’s expertise in cardiovascular, renal, and metabolic diseases. The collaboration focuses on addressing the urgent need for effective treatments to halt NASH progression and restore liver function. Boehringer Ingelheim, a Germany-based pharmaceutical company, is actively engaged in developing therapies for metabolic dysfunction-associated steatohepatitis (MASH).

Major companies operating in the metabolic dysfunction-associated steatohepatitis (mash) treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, Novartis AG, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Apollo Health and Lifestyle Limited, Jenny Craig, Nutrisystem, Madrigal Pharmaceuticals, Anoos Clinic, Galectin Therapeutics Inc., Galmed Pharmaceuticals, Hepion Pharmaceuticals, Inventiva, NGM Biopharmaceuticals, Sagimet Biosciences, Viking Therapeutics, Terns Pharma, Genfit SA.

North America was the largest region in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metabolic dysfunction-associated steatohepatitis (mash) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the metabolic dysfunction-associated steatohepatitis (mash) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs on pharmaceutical ingredients, medical devices, and diagnostic equipment used in MASH treatment have increased overall treatment costs and slowed availability in regions dependent on imports, especially Asia-Pacific and South America. These tariffs mainly affect drug manufacturers, diagnostic centers, and specialty clinics sourcing advanced liver testing devices. However, tariffs have also encouraged domestic production and research investment, which may improve long-term accessibility and lower dependency on imported medical technologies.

The metabolic dysfunction-associated steatohepatitis (mash) treatment market research report is one of a series of new reports that provides metabolic dysfunction-associated steatohepatitis (mash) treatment market statistics, including metabolic dysfunction-associated steatohepatitis (mash) treatment industry global market size, regional shares, competitors with a metabolic dysfunction-associated steatohepatitis (mash) treatment market share, detailed metabolic dysfunction-associated steatohepatitis (mash) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the metabolic dysfunction-associated steatohepatitis (mash) treatment industry. This metabolic dysfunction-associated steatohepatitis (mash) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Metabolic dysfunction-associated steatohepatitis (MASH) treatment refers to medical and lifestyle interventions aimed at addressing inflammation and liver damage caused by fat accumulation in the liver associated with metabolic dysfunctions like obesity, diabetes, and insulin resistance, focusing on improving liver health and metabolic outcomes.

The main treatments in metabolic dysfunction-associated steatohepatitis (MASH) treatment are drug and therapy. Drug treatment refers to the use of pharmaceutical therapies aimed at reducing liver inflammation, fibrosis, and fat accumulation associated with the condition, with the goal of improving liver function and preventing disease progression. The end users of this are hospitals, specialty clinics, homecare, and others, and are distributed by various channels such as hospital pharmacies, online pharmacies, and retail pharmacies.

The metabolic dysfunction-associated steatohepatitis (MASH) treatment market consists of revenues earned by entities by providing services such as clinical care services, nutritional counseling, pharmacotherapy management, patient education, and support programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The metabolic dysfunction-associated steatohepatitis (MASH) treatment market also includes sales of antioxidants, antidiabetic drugs, and liver protective supplements. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.